Accounts Receivable, after Allowance for Credit Loss, Current of MADRIGAL PHARMACEUTICALS, INC. from 31 Dec 2023 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
- Summary
-
MADRIGAL PHARMACEUTICALS, INC. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
- MADRIGAL PHARMACEUTICALS, INC. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $134,476,000, a 150% increase year-over-year.
- Source SEC data
- View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)
MADRIGAL PHARMACEUTICALS, INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $134,476,000 | +$80,654,000 | +150% | 31 Dec 2025 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2025 | $113,285,000 | +$82,822,000 | +272% | 30 Sep 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q2 2025 | $79,231,000 | +$72,332,000 | +1048% | 30 Jun 2025 | 10-Q | 05 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $61,428,000 | 31 Mar 2025 | 10-Q | 01 May 2025 | 2025 | Q1 | ||
| Q4 2024 | $53,822,000 | +$53,822,000 | 31 Dec 2024 | 10-K | 19 Feb 2026 | 2025 | FY | |
| Q3 2024 | $30,463,000 | 30 Sep 2024 | 10-Q | 31 Oct 2024 | 2024 | Q3 | ||
| Q2 2024 | $6,899,000 | 30 Jun 2024 | 10-Q | 07 Aug 2024 | 2024 | Q2 | ||
| Q4 2023 | $0 | 31 Dec 2023 | 10-K | 26 Feb 2025 | 2024 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.